Efficacy and safety of pyrimidine nucleos(t)ide therapy in thymidine kinase 2 deficiency
Michio Hirano, Caterina Garone, Richard Haas, Carmen Paradas, Fernando Scaglia, Irene Rebollo Mesa, Carl Chiang, Anny-Odile Colson, Susan VanMeter, Cristina Domínguez-González · 2026
Read Efficacy and safety of pyrimidine nucleos(t)ide therapy in thymidine kinase 2 deficiency by Michio Hirano, Caterina Garone, Richard Haas, Carmen Paradas, Fernando Scaglia, Irene Rebollo Mesa, Carl Chiang, Anny-Odile Colson, Susan VanMeter, Cristina Domínguez-González (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13273412.txt.
Description
Michio Hirano and a large team assessed pyrimidine nucleoside therapy for thymidine kinase 2 deficiency in a 2026 pooled study. This ultra rare inherited disease drains mitochondrial DNA, causing progressive muscle weakness and breathing failure. Until a recent drug approval, care was only supportive.
The team pooled 218 patients from trials, access programs, literature, and chart reviews, with 104 treated and 114 untreated. Most had symptoms start by age twelve. In that early onset group, treated patients lived far longer on average than untreated patients across thirty years of follow-up. Loss of motor milestones was more common before treatment than after it began. The study also tracked breathing and feeding support plus safety across the pooled groups.
Catalog record
| CREATOR | Michio Hirano, Caterina Garone, Richard Haas, Carmen Paradas, Fernando Scaglia, Irene Rebollo Mesa, Carl Chiang, Anny-Odile Colson, Susan VanMeter, Cristina Domínguez-González |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |